These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30219699)

  • 1. Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.
    Watts NL; Marques MB; Peavey DB; Innis-Shelton R; Saad A; Ad S; Salzman D; Lamb LS; Costa LJ
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):233-238. PubMed ID: 30219699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
    Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.
    Sanikommu SR; Reese ES; He J; Lee C; Ai J; Butler CM; Jacobs R; Hu B; Atrash S; Trivedi J; Bhutani M; Voorhees P; Usmani SZ; Ghosh N; Fasan O; Druhan LJ; Symanowski J; Copelan EA; Avalos BR
    J Clin Apher; 2021 Aug; 36(4):553-562. PubMed ID: 33710672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34
    Partanen A; Turunen A; Valtola J; Vasala K; Ågren L; Penttilä K; Pyörälä M; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    J Clin Apher; 2020 Aug; 35(4):255-263. PubMed ID: 32311780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study on the efficacy of pegfilgrastim-filgrastim combination regimen in the mobilization for autologous stem cell transplantation in lymphoma patients.
    Wang X; Guo W; Li J; Li J; Zhao Y; Du B; Bai O
    Am J Med Sci; 2024 Jul; ():. PubMed ID: 39089426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
    Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34
    Partanen A; Valtola J; Ropponen A; Kuitunen H; Kuittinen O; Vasala K; Ågren L; Penttilä K; Keskinen L; Pyörälä M; Nousiainen T; Selander T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2019 Jan; 59(1):325-334. PubMed ID: 30450652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A; Vítová V; Kořístek Z; Lysák D
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization--cost-effectiveness analysis.
    Abusin GA; Abu-Arja RF; Gingrich RD; Silverman MD; Zamba GK; Schlueter AJ
    J Clin Apher; 2013 Aug; 28(4):293-300. PubMed ID: 23426644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
    Zhuang L; Boriboonnangkul P; Wang S; Yuan S
    Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.